The field of biologics is vast and growing, with tremendous potential to improve patients’ lives and public health.
Access to quality raw materials and increased stakeholder collaboration are needed to help ensure availability of monoclonal antibody (mAb) treatments for COVID-19 in low- and middle-income countries (LMICs).
COVID-19 is transforming our ways of thinking about the development, manufacture and delivery of critical medicines to patients around the world.
The scale and speed of the global vaccine research and development effort in response to COVID-19 is unprecedented.
The spread of COVID-19 has been a wake-up call to the world about dangers posed by over-reliance on single-country sources in the global medicine supply chain.
Innovations in biotherapeutic medicines are advancing at an unprecedented pace and offer great promise for improving outcomes for patients.
What happens when patients who receive a trusted treatment start experiencing adverse reactions? And what can be done to help prevent it from reoccurring?
Patients, their families and health care providers alike care about the quality of their medicines. For nearly 200 years, USP has contributed to the quality of medicines by providing publicly-available standards.
Show 11 More